Organization
Juntendo University School of Medicine
4 abstracts
Abstract
Five-year survival outcomes from the PIT-1 trial: Pemetrexed-cisplatin plus bevacizumab or concurrent thoracic radiation therapy followed by surgery in stage IIIA (N2) nonsquamous non-small cell lung cancer.Org: Juntendo University School of Medicine, Tokyo Bay Makuhari Clinic for Advanced Imaging, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,
Abstract
CRES3T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor.Org: Juntendo University School of Medicine, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Hiroshima University, National Cancer Center Hospital Japan East, Kashiwa, Japan, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in adults aged older than 75 years.Org: Kansai Medical University Hospital, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, National Cancer Center Hospital East, Kashiwa, Japan, Kitasato Daigaku Igakubu, Sagamihara-Shi Minami-Ku, Japan,
Abstract
Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY).Org: Department of Thoraci surgery, National Cancer Center Hospital East, Kashiwa, Japan, Division of Thoracic and Thyroid Surgery, Tokyo Medical University, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan,